Molecular Dx Company Biocartis ‘At Inflection Point’ As It Eyes Infectious Disease Market
Executive Summary
Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.